| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/10/2001 | EP1140120A2 Human brainiac-5 |
| 10/10/2001 | EP1140118A1 Cyclic adenosine diphosphate ribose analogues for modulating t cell activity |
| 10/10/2001 | EP1140106A1 Treatment of diseases involving cyst formation |
| 10/10/2001 | EP1140100A2 Use of (s)-triazines for treating apicomplexan parasitic infections |
| 10/10/2001 | EP1140092A2 Method of treating sexual disturbances |
| 10/10/2001 | EP1140085A1 Azabicycloalkanes as ccr5 modulators |
| 10/10/2001 | EP1140081A2 Improving mental performance by increasing brain insulin sensitivity |
| 10/10/2001 | EP1140079A1 Assays for ligands for nuclear receptors |
| 10/10/2001 | EP1140077A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 10/10/2001 | EP1140076A1 Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome |
| 10/10/2001 | EP1140075A1 Treatment of retroviral infections with oxyphenbutazone |
| 10/10/2001 | EP1140073A1 Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer |
| 10/10/2001 | EP1140071A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| 10/10/2001 | EP1140069A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR |
| 10/10/2001 | EP1140067A1 Antiviral method using mek inhibitors |
| 10/10/2001 | EP1140066A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| 10/10/2001 | EP1140065A1 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease |
| 10/10/2001 | EP1140062A2 Treatment of asthma with mek inhibitors |
| 10/10/2001 | EP1140056A2 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life |
| 10/10/2001 | EP1140055A1 Use of a 5ht 2a? and 5ht 2a/c? receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
| 10/10/2001 | EP1140054A2 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |
| 10/10/2001 | EP1140052A2 Sensitizing agents for the treatment of skin lesions |
| 10/10/2001 | EP1140051A2 Use or tertbutylhydroquinone for lowering blood cholesterol and/or blood triglycerides |
| 10/10/2001 | EP1140050A2 A composition useful to treat periodontal disease |
| 10/10/2001 | EP1140048A2 Methods for treating certain diseases using naaladase inhibitors |
| 10/10/2001 | EP1140047A2 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs |
| 10/10/2001 | EP1140046A1 Use of a mek inhibitor for preventing transplant rejection |
| 10/10/2001 | EP1140045A2 Homer a new target of treating psychiatric disorders |
| 10/10/2001 | EP1140044A2 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION |
| 10/10/2001 | EP1140042A1 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites |
| 10/10/2001 | EP1140041A2 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 10/10/2001 | EP1140040A1 Spray-type cosmetic composition and matrix used in said composition for dermal administration |
| 10/10/2001 | EP1140028A1 Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 10/10/2001 | EP1140027A1 Dosage forms comprising porous particles |
| 10/10/2001 | EP1140026A1 Biodegradble polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 10/10/2001 | EP1140020A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 10/10/2001 | EP1140019A1 Aerosol formulations for buccal and pulmonary application |
| 10/10/2001 | EP1140018A1 Polyol/oil suspensions for the sustained release of proteins |
| 10/10/2001 | EP1140010A2 Substrate composition and method of use for sequestration of skin irritants |
| 10/10/2001 | EP1140009A2 Absorbent article composition and method of use for sequestering skin irritants |
| 10/10/2001 | EP1140001A2 Composition for treatment of burns |
| 10/10/2001 | EP1140000A1 Osmetische oder dermatologische zusammensetzub |
| 10/10/2001 | EP1139972A1 Dihydropyrimidines and uses thereof |
| 10/10/2001 | EP1139913A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 10/10/2001 | EP1139793A2 Inhibitors of the bitter taste response |
| 10/10/2001 | EP1139753A1 Formulations for treating disease and methods of using same |
| 10/10/2001 | EP1139752A1 Methods and compositions for treatment of cell proliferative disorders |
| 10/10/2001 | EP1139746A1 Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| 10/10/2001 | EP1093378A4 Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots |
| 10/10/2001 | EP0956036A4 Anti-fibrotic agent assay |
| 10/10/2001 | EP0840620B1 Il-8 antagonists for treatment of asthma |
| 10/10/2001 | CN1317047A GBS toxin receptor |
| 10/10/2001 | CN1317013A Peptide fragments of cholera toxic B or enterotoxin B as vaccine adjuvants |
| 10/10/2001 | CN1317005A Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 10/10/2001 | CN1316908A Neuroprotection |
| 10/10/2001 | CN1316901A The use of fumaric acid derivatives in transplant medicine |
| 10/09/2001 | US6300492 Nucleotide sequences for the prevention of suppression of apoptosis and treatment lymphoma, leukemia, melanoma, ovarian, mammary gland, pancreatic and lung cancers |
| 10/09/2001 | US6300472 Rab proteins |
| 10/09/2001 | US6300377 Coenzyme Q products exhibiting high dissolution qualities |
| 10/09/2001 | US6300365 Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
| 10/09/2001 | US6300356 Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist |
| 10/09/2001 | US6300355 For therapy of cancer |
| 10/09/2001 | US6300350 Administering to mammal an retinoic acid (rar) agonist that is at least gamma selective and is rar.alpha. sparing for treating emphysema |
| 10/09/2001 | US6300335 Urogenital disorders |
| 10/09/2001 | US6300332 Methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| 10/09/2001 | US6300329 Heterocyclic pyrido(1,2-a)pyrazine compounds for treatment of parkinson's disease |
| 10/09/2001 | US6300327 Neurotropin inhibitors |
| 10/09/2001 | US6300322 Water solution with hydroxyethyl starch, sodium ion, chloride ion, potassium iion and calcium ion for plasma substitution |
| 10/09/2001 | US6300314 Admnistering heterocyclic peptides to stimulate hematopoiesis of cells |
| 10/09/2001 | US6300313 Means for treating prostate hypertrophy and prostate cancer |
| 10/09/2001 | US6300097 A polypeptide; therapy and diagnosis of bacterial infections; upper respiratory infections, toxic shock syndrome, septic arthritis and intestinal disorders |
| 10/09/2001 | US6300067 TFIIB transcription factor from Candida albicans and methods of screening for inhibitors of Candida albicans growth |
| 10/09/2001 | US6299903 Delayed release pharmaceutical formulation containing a β-lactam antibiotic |
| 10/09/2001 | US6299902 Absorption |
| 10/09/2001 | US6299900 Non-occlusive, percutaneous or transdermal drug delivery system |
| 10/09/2001 | US6299889 Stable ascorbic acid preparation for topical use |
| 10/09/2001 | US6299883 Tarf |
| 10/09/2001 | US6299877 Used in therapy |
| 10/09/2001 | US6299876 Cytotoxic drug therapy |
| 10/09/2001 | US6299869 Human interferon-epsilon: a type I interferon |
| 10/09/2001 | US6299868 Fat-binding polymers |
| 10/09/2001 | US6299858 Contacting living teleost post 12-hours of development with dye having affinity for dead cells and stains dead cells; administering agent to living teleost; detecting staining of dead cells with dye in specific tissue or organ; comparing |
| 10/09/2001 | CA2082825C Inhibition of viral infection |
| 10/07/2001 | CA2340936A1 Inhibitors for the formation of soluble human cd23 |
| 10/04/2001 | WO2001073133A1 Compositions and methods for identifying and targeting cancer cells |
| 10/04/2001 | WO2001073132A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 10/04/2001 | WO2001073131A1 High specificity marker detection |
| 10/04/2001 | WO2001073115A1 Method and kit for the screening, the detection and/or the quantification of transcriptional factors |
| 10/04/2001 | WO2001073035A1 A METHOD FOR SCREENING FOR AUTOIMMUNE DISEASE BY IDENTIFYING POLYMORPHISMS IN IL-12 p40 |
| 10/04/2001 | WO2001073034A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 10/04/2001 | WO2001073032A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 10/04/2001 | WO2001073029A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 10/04/2001 | WO2001073018A2 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 10/04/2001 | WO2001072977A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 10/04/2001 | WO2001072962A2 Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 10/04/2001 | WO2001072846A2 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 10/04/2001 | WO2001072841A2 Isolated human g-protein coupled receptors that are members of the aminergic subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 10/04/2001 | WO2001072840A2 Isolated human g-protein coupled receptors of the mas proto-oncogene subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 10/04/2001 | WO2001072839A2 Human g-protein coupled receptors |
| 10/04/2001 | WO2001072838A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |